Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-04-25
1999-09-07
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514801, 514808, 514825, 424678, 424682, 530356, 530840, A61K 3801, A61K 3823
Patent
active
059487666
DESCRIPTION:
BRIEF SUMMARY
The present invention pertains to the use of tasteless, hydrolyzed collagen from gelatin, gelatin or animal collagenic connective tissue having an average molecular weight of from 1 to 40 kD, and to agents containing the same.
From EP-B-0 254 289, there are known agents for the treatment of arthroses containing tasteless, enzymatically hydrolyzed collagen from animal skin, animal bones, sufficiently purified connective tissue, or gelatin, having an average molecular weight of from 10 to 80 kD.
DE-A-36 26 414 describes a preparation for stimulating chondrocytes and osteoblasts (ossein/hydroxyapatite complex), as well as methods for the preparation thereof and medicaments containing the same. The preparation is obtained by purifying and grinding bones and therefore contains native collagen. The most important component of the preparation, however, is the ossein/hydroxyapatite complex with its high calcium and phosphate contents.
JP-A-05 05 1400 describes the formation of a preparation from cell cultures of rabbit cartilage. The collagen has a molecular weight of 60 kD and consists of type II.
GB-PS-1 227 534 describes the preparation of a collagen hydrolysate by alkaline or acid pressure hydrolysis. In addition to degraded collagen, this preparation contains from 4 to 15% of free amino acids. The starting material is not specified. This preparation is preferably intended for use with calcium salts and is said to enable increased calcium supply.
Osteoporosis is defined as the clinical manifestation of bone atrophy. This means a reduction of the bone mass for a given volume. To date, more than 20 causes have been known for the occurrence of osteoporosis. The most frequent forms are postmenopausal and senile osteoporoses. From the beginning of the fifth decade of life, the whole bone mass begins to decrease.
This is due to the fact that from this point, there is more bone mass destroyed than formed. Osteoporosis is the most wide-spread metabolic disease of bone which increases with age, predominantly with females.
Three to five years after the menopause, there is usually a sudden occurrence of loss of bone mass. This is manifested by the occurrence of fractures of the spiny column, fractures of the femoral neck and of the forearm. Mostly, at the point of first occurrence of a fracture, only about 50% of the original bone mass are retained.
Early diagnosis of osteoporosis is a great problem since in the normal X-ray picture, it only shows after a loss of at least 30% of the bone mass.
Osteoporotic changes are also associated with a reduction of the number of collagen fibers of the bone. The degradation products of this collagen catabolism can be increasedly detected in the urine.
From a molecular point of view, the bone has a unique collagen composition. It is the only tissue in which type I collagen is not associated with type III collagen. The collagen structures are stabilized by cross-links which are effected by two amino acid residues of lysine and hydroxylysine.
Several other cross-linking possibilities have been described. Fujimoto (Biochem. Biophys. Res. Commun. 1977; 76: 1124-1129) describes cross-linking elements derived from three lysine or hydroxylysine residues, i.e. pyridinoline (PD) and deoxypyridinoline (DPD).
Their occurrence is connective tissue specific, but neither limited to a particular tissue type nor to a particular collagen type. It is known that collagens of types I, II, III, IX, X and XI can form this kind of cross-links.
These cross-links are not degraded by the body and are excreted with the urine. Therefore, their content in the urine is a good indicator of collagen degradation.
Agents for the treatment of osteoporosis include calcitonin, calcium salts, such as calcium fluoride and calcium bis(phosphonates), as well as progesterone.
It is the object of the present invention to provide further agents for the treatment of osteoporosis. This object has now been achieved by the use of tasteless, hydrolyzed collagen from gelatin, gelatin or animal collagenic connective tissue having an a
REFERENCES:
patent: 4804745 (1989-02-01), Koepff et al.
patent: 4919931 (1990-04-01), Goldner
patent: 5641747 (1997-06-01), Popoff et al.
CAS Registry No. 9000-70-8, Ossein, 1997.
Lugli, et al., Effect of Ossein Hydroxyapatie Compound (Ossan) on Back Pain in the Elderly. Results of a Placebo-Controlled Trial. Clin.Trials J., vol. 27, No. 3, pp. 141-148, 1990.
Dambacher, et al., The Drug Treatment of Osteopososis--The Present Position, Schweiz. Apoth. Ztg., vol. 125, No. 13, pp. 372-375, 1987.
Braumer Klaus
Eggersgluss Bernd
Milan Adam
Schrieber Reinhard
DGF Stoess AG
Tsang Cecilia J.
LandOfFree
Use of tasteless, hydrolyzed collagen and agent containing the s does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of tasteless, hydrolyzed collagen and agent containing the s, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of tasteless, hydrolyzed collagen and agent containing the s will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1804620